Penpulimab, an fc-engineered igg1 anti-pd-1 antibody, with improved efficacy and low incidence of immune-related adverse events

HIGHLIGHTS

• who: Zhaoliang Huang from the Biopharma Co, Ltd, Zhongshan, China, Akeso Biopharma Co., Ltd., Zhongshan, China Tel Aviv University, Israel have published the paper: Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events, in the Journal: (JOURNAL)
• what: This study showed that similar to nivolumab, penpulimab significantly promoted IFN-g and IL-2 production by T_cells in_vitro.
• how: IrAEs To examine the effects on clinical safety of the Fc engineering design on an IgG1 backbone for penpulimab the authors analyzed irAEs in . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.